20 articles
Women with RA using treat-to-target therapy achieved pregnancy 3x faster than those with standard care, with 77% conceiving within one year.
Study reveals how inflammation blocks growth hormone production and tests whether etanercept can restore healthy levels in women with RA.
Small study tests whether tocilizumab can achieve faster, deeper remission in newly diagnosed rheumatoid arthritis patients.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
A Phase 4 trial tests whether simplifying HIV treatment to two drugs worsens hidden viral replication and immune dysfunction.
New research reveals how androgens enhance monocytes' ability to provide natural pain relief through immune pathways.
Revolutionary cell therapy achieves drug-free remission in patients with severe myasthenia gravis, an autoimmune muscle disorder.
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
A 2025 meta-analysis of 11 RCTs finds Tฮฑ1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
A new in vitro study shows Thymosin ฮฑ1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
A cluster randomized trial tests whether couples counseling plus stigma workshops can boost PrEP/ART uptake among young South African adults.
NYU study reveals how targeted immune therapy transforms inflammatory responses in rheumatoid arthritis treatment.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
A rigorous 2025 review finds no approved AMR therapy and reassesses all current evidence, spotlighting CD38 antibodies and complement inhibition.
A German proof-of-concept trial tests whether a maximal five-class antiretroviral regimen can deplete latent HIV reservoirs.
48-week trial shows biological drugs don't outperform standard treatment for patient-reported outcomes in early rheumatoid arthritis.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Revolutionary cancer treatment successfully treats treatment-resistant autoimmune disease, offering hope for severe cases.
Combining targeted therapies may help patients with severe hidradenitis suppurativa who don't respond to standard treatments.
New research shows how targeted interleukin-2 treatment can restore regulatory T cells and reduce muscle inflammation in autoimmune conditions.
